Amgen exits TScan TCR discovery collaboration tied to over USD 500m in milestones
Amgen (NASDAQ: AMGN) terminated its collaboration with TScan Therapeutics (NASDAQ: TCRX), ending over USD 500 million in potential milestone payments for TScan. The agreement, effective November 10, 2026, focused on TScan's T-cell receptor discovery platform for Crohn's disease. TScan reported progress in its Phase III ALLOHA-2 trial for TSC-101, a therapy for hematologic malignancies, with topline data expected mid-2028.
How this was made
The 30-second read
Why it matters
Both companies adjust forward outlooks; Amgen sheds a non‑core asset, TScan loses a major revenue source.
Market read
Primary corporate action affecting two listed biotech firms; material for traders monitoring partnership risk.
What to watch
TScan's oncology pipeline remains strong with Phase III trial dosing, which could offset the loss.
Background
The termination follows a standard 90‑day notice clause; no early penalty applies.
Ticker impact
Amgen terminated its TScan TCR discovery collaboration, removing over $500 million in potential milestone payments.
minor downward pressure on AMGN, limited volatility
The termination removes a sizable upside but does not affect Amgen's core pipeline; investors may view it as a cost‑saving.
TScan Therapeutics lost a collaboration with Amgen that could have generated more than $500 million in milestones.
downward move expected for TCRX
TCRX's financial outlook was adjusted to remove the $500 M milestone potential, a material hit to its valuation.
Market effects
Highlights risk in biotech collaborations and may prompt scrutiny of similar partnership structures.
US biotech sector may see modest re‑rating of partnership‑dependent stocks.
Limited to investors tracking biotech collaboration pipelines.
Counterpoint
Amgen may reallocate resources to higher‑impact projects, potentially benefiting its core pipeline.
Key entities
- CompanyAmgen
US‑listed biotech giant
- CompanyTScan Therapeutics
NASDAQ‑listed TCR discovery firm
